These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 3743371)
41. Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines. Sladek NE; Low JE; Landkamer GJ Cancer Res; 1985 Feb; 45(2):625-9. PubMed ID: 3967238 [TBL] [Abstract][Full Text] [Related]
42. Antitumor activity of monomeric and polymeric cyclophosphamide derivatives compared with in vitro hydrolysis. Hirano T; Ringsdorf H; Zaharko DS Cancer Res; 1980 Jul; 40(7):2263-7. PubMed ID: 7388792 [TBL] [Abstract][Full Text] [Related]
43. Immunogenicity of cyclophosphamide-treated leukaemia cells. Kawalec M; Jakóbisiak M; Skórski T; Kawiak J Folia Biol (Praha); 1982; 28(5):334-43. PubMed ID: 6816636 [TBL] [Abstract][Full Text] [Related]
44. Synthesis and antitumour activity of several new 4-aroyl-1-nitrosohydrazinecarboxamides. Gugova R; Topakbashian V; Lozeva S; Dimov S; Golovinsky E Drugs Exp Clin Res; 1997; 23(2):71-5. PubMed ID: 9309382 [TBL] [Abstract][Full Text] [Related]
45. Characterization of active phosphorus surface sites at synthetic carbonate-free fluorapatite using single-pulse 1H, 31P, and 31P CP MAS NMR. Jarlbring M; Sandström DE; Antzutkin ON; Forsling W Langmuir; 2006 May; 22(10):4787-92. PubMed ID: 16649796 [TBL] [Abstract][Full Text] [Related]
46. Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies. Sonawat HM; Leibfritz D; Engel J; Hilgard P Biochim Biophys Acta; 1990 Apr; 1052(1):36-41. PubMed ID: 2322593 [TBL] [Abstract][Full Text] [Related]
47. Chemical and biological evaluation of hydrolysis products of cyclophosphamide. Gilard V; Martino R; Malet-Martino MC; Kutscher B; Müller A; Niemeyer U; Pohl J; Polymeropoulos EE J Med Chem; 1994 Nov; 37(23):3986-93. PubMed ID: 7966159 [TBL] [Abstract][Full Text] [Related]
48. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. 2. Direct observation, characterization, and reactivity studies of iminocyclophosphamide and related species. Boyd VL; Summers MF; Ludeman SM; Egan W; Zon G; Regan JB J Med Chem; 1987 Feb; 30(2):366-74. PubMed ID: 3806617 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX. Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539 [No Abstract] [Full Text] [Related]
50. Half-life of oxazaphosphorines in biological fluids. Sladek NE; Powers JF; Grage GM Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904 [TBL] [Abstract][Full Text] [Related]
51. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia. Klubes P; Cerna I Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161 [TBL] [Abstract][Full Text] [Related]
52. O-imino esters of N,N-bis(2-chloroethyl)phosphorodiamidic acid. Synthesis, X-ray structure determination, and anticancer evaluation. Ludeman SM; Shao KL; Zon G; Himes VL; Mighell AD; Takagi S; Mizuta K J Med Chem; 1983 Dec; 26(12):1788-90. PubMed ID: 6644750 [TBL] [Abstract][Full Text] [Related]
53. Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 1: In vitro investigations on the kinetics of activated isophosphamide metabolites and the determination of selective properties of DNA-interstrand and DNA-protein crosslinking mechanisms using 31P-NMR spectroscopy. Ulmer W Strahlenther Onkol; 1991 Jul; 167(7):427-33. PubMed ID: 1858021 [TBL] [Abstract][Full Text] [Related]
54. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592 [TBL] [Abstract][Full Text] [Related]
55. Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrast enhanced imaging. Poptani H; Bansal N; Graham RA; Mancuso A; Nelson DS; Glickson JD NMR Biomed; 2003 Apr; 16(2):102-11. PubMed ID: 12730951 [TBL] [Abstract][Full Text] [Related]
56. Organometallic anticancer agents: cellular uptake and cytotoxicity studies on thiol derivatives of the antitumor agent molybdocene dichloride. Waern JB; Dillon CT; Harding MM J Med Chem; 2005 Mar; 48(6):2093-9. PubMed ID: 15771451 [TBL] [Abstract][Full Text] [Related]
57. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers. Low JE; Borch RF; Sladek NE Cancer Res; 1983 Dec; 43(12 Pt 1):5815-20. PubMed ID: 6640533 [TBL] [Abstract][Full Text] [Related]
58. Identification of metabolism pathways of anticancer drugs by high-pressure liquid chromatography in combination with field desorption mass spectrometry. Przybylski M Arzneimittelforschung; 1982; 32(9):995-1012. PubMed ID: 6756419 [TBL] [Abstract][Full Text] [Related]
59. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Sladek NE; Landkamer GJ Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623 [TBL] [Abstract][Full Text] [Related]
60. 1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards. Springer JB; Chang YH; Koo KI; Colvin OM; Colvin ME; Dolan ME; Delaney SM; Flowers JL; Ludeman SM Chem Res Toxicol; 2004 Sep; 17(9):1217-26. PubMed ID: 15377155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]